Search

Now showing items 1-2 of 2

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study

original article

open access

published version

Svatoň, Martin

;

Knetki-Wroblewska, Magdalena

;

Hošek, Petr

;

Chowaniecova, Gabriela

;

Špaček, Jan

;

Fischer, Ondřej

;

Bílek, Ondřej

;

Hrnčiarik, Michal

;

Kauffmann-Guerrero, Diego

2025

Ivyspring International Publisher

Journal of Cancer

16 (10)

Background: Patients with non-small cell lung cancer (NSCLC) with PD-Ll expression ~ 50% can be treated with immunotherapy alone or with a combination of immunotherapy and chemotherapy. One of these options is treatment ...

Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab

original article

open access

published version

Fiala, Ondřej

;

Hošek, Petr

;

Tkadlecová, Michaela

;

Melichar, Bohuslav

;

Zemánková, Anežka

;

Kopecký, Jindřich

;

Vočka, Michal

;

Matějů, Martin

;

Lohynská, Radka

;

Šiková, Dominika

;

Stránský, Petr

;

Študentová, Hana

;

Spisarová, Martina

;

Nováková, Hana

;

Priester, Peter

;

Kryštofová, Dominika

;

Grmelová, Lucie

;

Büchler, Tomáš

;

Poprach, Alexandr

2025

Clinical & Experimental Metastasis

42 (5)

Renal cell cancer (RCC) is typically a disease of older adults, who often have comorbidities requiring the use of multiple concomitant medications. Even though the patients with metastatic RCC (mRCC) are often exposed to ...

Search

Filters

Pembrolizumab versus Pembrolizumab plus Chemotherapy in Non-small Cell Lung Cancer with High PD-L1 Expression - Multicenter Real-world Evidence Study

original article

open access

published version

Svatoň, Martin

Knetki-Wroblewska, Magdalena

Hošek, Petr

Chowaniecova, Gabriela

Špaček, Jan

Fischer, Ondřej

Bílek, Ondřej

Hrnčiarik, Michal

Kauffmann-Guerrero, Diego

2025

Ivyspring International Publisher

Journal of Cancer

16

(10)

Background: Patients with non-small cell lung cancer (NSCLC) with PD-Ll expression ~ 50% can be treated with immunotherapy alone or with a combination of immunotherapy and chemotherapy. One of these options is treatment ...

Impact of concomitant use of proton pump inhibitors or cardiovascular medication on survival outcomes of patients with metastatic renal cell carcinoma treated with nivolumab

original article

open access

published version

Fiala, Ondřej

Hošek, Petr

Tkadlecová, Michaela

Melichar, Bohuslav

Zemánková, Anežka

Kopecký, Jindřich

Vočka, Michal

Matějů, Martin

Lohynská, Radka

Šiková, Dominika

Stránský, Petr

Študentová, Hana

Spisarová, Martina

Nováková, Hana

Priester, Peter

Kryštofová, Dominika

Grmelová, Lucie

Büchler, Tomáš

Poprach, Alexandr

2025

Clinical & Experimental Metastasis

42

(5)

Renal cell cancer (RCC) is typically a disease of older adults, who often have comorbidities requiring the use of multiple concomitant medications. Even though the patients with metastatic RCC (mRCC) are often exposed to ...